[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-zentalis-pharmaceuticals-inc-n330194d846-4217-7f7c-89d5-83f61e548824":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":11,"showTags":12,"source":13,"reactions":14,"selfReactions":15,"logo":16,"sourceId":17,"sourceUserId":18,"asset":19,"tagsCategories":20,"totalComments":21,"lang":22,"unique_views_count":23,"enrichStatus":19,"triageKind":18,"triageImportance":18,"expandEligible":18,"summarizeEligible":18,"eventEligible":18,"eventType":18,"eventAction":18},"zentalis-pharmaceuticals-inc-n330194d846-4217-7f7c-89d5-83f61e548824","1738794934000","Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka Purchases 60,000 Shares","Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) Director Jan Skvarka bought 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.","https://www.marketbeat.com/instant-alerts/zentalis-pharmaceuticals-inc-nasdaqzntl-director-jan-skvarka-purchases-60000-shares-2025-02-04/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","[\"-\"]","[{\"name\":\"-\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/protocols/-.png\"}]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Other\"]","0","EN","2"]